Medtronic (NYSE:MDT) today shared data supporting the use of its MiniMed 780G automated insulin delivery system in a range of patients.
Our sister site, Drug Delivery Business News, reports today that the medtech giant highlighted improved glycemic outcomes for those with type 2 diabetes and in young children. Investigators shared data at the American Diabetes Association’s 85th Scientific Sessions in Chicago.
In one study, participants with insulin-intensive type 2 diabetes using MiniMed 780G (under investigational use) achieved an average 8.6% increase in time in range. They reached 84.9% time in range — well ahead of ADA’s 70% goal. The HbA1C reduction from 7.7% to 6.9% met ADA targets, too.
Separately, Medtronic reported data from the LENNY trial, also published in The Lancet Diabetes & Endocrinology. The multi-center trial evaluated MiniMed 780G in young children (ages 2-6) with type 1 diabetes in a home setting.
Get the full story at our sister site, Drug Delivery Business News.
